MSP3-CRM-Vac4All/ Alhydrogel

Phase 1Biologic

VVac4All

MSP3-CRM-Vac4All/ Alhydrogel is one of 21 biologic programs targeting Malaria. It is currently in Phase 1.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

MalariaActive, not recruiting

MalariaPhase 1

Active, not recruiting

Competition

Competitive Landscape

479 competitors in Malaria

#DrugCompanyPhaseTrials

Biltricide

Bayer

Preclinical

1 2

Stelara

Johnson & Johnson

Preclinical

—3

Hydroxychloroquine Sulfate

Novartis

Preclinical

—4

Iron

WWatson Pharmaceuticals

Preclinical

1 5

IV LBH589

Novartis

Preclinical

1 6

MSP3-CRM-Vac4All/ Alhydrogel

VVac4All

Phase 1

1 7

Mefloquine Plus Artesunate

Medicines for Malaria Venture

Preclinical

1 8

IV Ceftriaxone

RRESnTEC, Institute of Research

Preclinical

1 9

RTS,S/AS01E

GSK

Preclinical

4 10

Malarone

Medicines for Malaria Venture

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Vaccine1 trial

MSP3-CRM-Vac4All/ Alhydrogel® Vaccine

Unknown status·VVac4All·Phase 1/2·NCT05776017·465 enrolled

Malaria1 trial

MSP3-CRM-Vac4All/ Alhydrogel® Malaria Vaccine

Unknown status·VVac4All·Phase 1·NCT05197751·42 enrolled

Sources

References

[1]
ClinicalTrials.gov — 2 trial records for MSP3-CRM-Vac4All/ Alhydrogel. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — MSP3-CRM-Vac4All/ Alhydrogel compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for MSP3-CRM-Vac4All/ Alhydrogel. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Vac4All company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Biologic[2]
Highest Phase: Phase 1[1]
Company: VVac4All

MSP3-CRM-Vac4All/ Alhydrogel

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

Vaccine1 trial

Malaria1 trial

References

Drug Info

Quick Facts

Related News